
Paul A Goepfert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1649024/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7552-7557.	3.3	1,708
2	HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood, 2006, 107, 4781-4789.	0.6	1,681
3	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science, 2010, 330, 1551-1557.	6.0	1,054
4	Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. Journal of Virology, 2005, 79, 10108-10125.	1.5	1,025
5	Magnitude of Functional CD8 + T-Cell Responses to the Gag Protein of Human Immunodeficiency Virus Type 1 Correlates Inversely with Viral Load in Plasma. Journal of Virology, 2002, 76, 2298-2305.	1.5	331
6	Perforin Expression Directly Ex Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control. PLoS Pathogens, 2010, 6, e1000917.	2.1	284
7	Escape and Compensation from Early HLA-B57-Mediated Cytotoxic T-Lymphocyte Pressure on Human Immunodeficiency Virus Type 1 Gag Alter Capsid Interactions with Cyclophilin A. Journal of Virology, 2007, 81, 12608-12618.	1.5	241
8	Selection bias at the heterosexual HIV-1 transmission bottleneck. Science, 2014, 345, 1254031.	6.0	225
9	Immune Suppression by Neutrophils in HIV-1 Infection: Role of PD-L1/PD-1 Pathway. PLoS Pathogens, 2014, 10, e1003993.	2.1	217
10	Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. Journal of Experimental Medicine, 2008, 205, 1009-1017.	4.2	203
11	Compensatory Mutation Partially Restores Fitness and Delays Reversion of Escape Mutation within the Immunodominant HLA-B*5703-Restricted Gag Epitope in Chronic Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2007, 81, 8346-8351.	1.5	197
12	A Significant Number of Human Immunodeficiency Virus Epitope-Specific Cytotoxic T Lymphocytes Detected by Tetramer Binding Do Not Produce Gamma Interferon. Journal of Virology, 2000, 74, 10249-10255.	1.5	182
13	Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703–positive individuals and their transmission recipients. Journal of Experimental Medicine, 2009, 206, 909-921.	4.2	165
14	Modeling sequence evolution in acute HIV-1 infection. Journal of Theoretical Biology, 2009, 261, 341-360.	0.8	162
15	Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles. Journal of Infectious Diseases, 2011, 203, 610-619.	1.9	151
16	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). PLoS ONE, 2011, 6, e21225.	1.1	131
17	QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans. Vaccine, 2001, 19, 2080-2091.	1.7	128
18	Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4512-4517.	3.3	126

#	Article	IF	CITATIONS
19	TOX is expressed by exhausted and polyfunctional human effector memory CD8 ⁺ T cells. Science Immunology, 2020, 5, .	5.6	125
20	Molecular Ecology and Natural History of Simian Foamy Virus Infection in Wild-Living Chimpanzees. PLoS Pathogens, 2008, 4, e1000097.	2.1	122
21	Antigen Burden Is a Major Determinant of Human Immunodeficiency Virus–Specific CD8+T Cell Maturation State: Potential Implications for Therapeutic Immunization. Journal of Infectious Diseases, 2003, 187, 364-374.	1.9	115
22	Glycoprotein B Vaccine Is Capable of Boosting Both Antibody and CD4 T-Cell Responses to Cytomegalovirus in Chronically Infected Women. Journal of Infectious Diseases, 2011, 203, 1534-1541.	1.9	103
23	Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. Journal of Clinical Investigation, 2021, 131, .	3.9	103
24	Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. Lancet Infectious Diseases, The, 2021, 21, 1257-1270.	4.6	99
25	HIV-1 Epitope-Specific CD8+ T Cell Responses Strongly Associated with Delayed Disease Progression Cross-Recognize Epitope Variants Efficiently. Journal of Immunology, 2006, 176, 6130-6146.	0.4	97
26	Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial. Open Forum Infectious Diseases, 2015, 2, ofv040.	0.4	92
27	Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1–Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 254-261.	0.9	88
28	Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4 ⁺ T cells, and disease progression. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1480-9.	3.3	87
29	Impact of pre-adapted HIV transmission. Nature Medicine, 2016, 22, 606-613.	15.2	87
30	Role of Transmitted Gag CTL Polymorphisms in Defining Replicative Capacity and Early HIV-1 Pathogenesis. PLoS Pathogens, 2012, 8, e1003041.	2.1	86
31	Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine, 2007, 25, 510-518.	1.7	85
32	Interleukin-21-Producing HIV-1-Specific CD8 T Cells Are Preferentially Seen in Elite Controllers. Journal of Virology, 2011, 85, 2316-2324.	1.5	81
33	Breast Milk-Derived Antigen-Specific CD8+ T Cells: An Extralymphoid Effector Memory Cell Population in Humans. Journal of Immunology, 2005, 174, 2951-2956.	0.4	79
34	Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles. Journal of Infectious Diseases, 2014, 210, 99-110.	1.9	73
35	CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription. Journal of Experimental Medicine, 2010, 207, 51-59.	4.2	69
36	Highâ€Dose Recombinant Canarypox Vaccine Expressing HIVâ€1 Protein, in Seronegative Human Subjects. Journal of Infectious Diseases, 2005, 192, 1249-1259.	1.9	66

#	Article	IF	CITATIONS
37	Multifunctional T-Cell Characteristics Induced by a Polyvalent DNA Prime/Protein Boost Human Immunodeficiency Virus Type 1 Vaccine Regimen Given to Healthy Adults Are Dependent on the Route and Dose of Administration. Journal of Virology, 2008, 82, 6458-6469.	1.5	66
38	SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. PLoS Pathogens, 2021, 17, e1009761.	2.1	66
39	HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells. Retrovirology, 2016, 13, 1.	0.9	63
40	Human Immunodeficiency Virus-Specific CD8 + T Cells in Human Breast Milk. Journal of Virology, 2002, 76, 7365-7373.	1.5	60
41	Characterization of Programmed Death-1 Homologue-1 (PD-1H) Expression and Function in Normal and HIV Infected Individuals. PLoS ONE, 2014, 9, e109103.	1.1	60
42	Comparison of Systemic and Mucosal Delivery of 2 Canarypox Virus Vaccines Expressing either HIVâ€1 Genes or the Gene for Rabies Virus G Protein. Journal of Infectious Diseases, 2004, 189, 1221-1231.	1.9	59
43	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV,the, 2020, 7, e688-e698.	2.1	58
44	Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. Cell Reports Medicine, 2021, 2, 100218.	3.3	57
45	Cumulative Impact of Host and Viral Factors on HIV-1 Viral-Load Control during Early Infection. Journal of Virology, 2013, 87, 708-715.	1.5	49
46	A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsâ~†â~†â~†. Vaccine, 2011, 29, 1948-1958.	1.7	48
47	Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans. Vaccine, 2014, 32, 5490-5495.	1.7	48
48	Transmitted Virus Fitness and Host T Cell Responses Collectively Define Divergent Infection Outcomes in Two HIV-1 Recipients. PLoS Pathogens, 2015, 11, e1004565.	2.1	44
49	Foamy Virus Envelope Clycoprotein Is Sufficient for Particle Budding and Release. Journal of Virology, 2003, 77, 2338-2348.	1.5	43
50	Profiles of Human Serum Antibody Responses Elicited by Three Leading HIV Vaccines Focusing on the Induction of Env-Specific Antibodies. PLoS ONE, 2010, 5, e13916.	1.1	43
51	CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides. Aids, 2005, 19, 241-50.	1.0	41
52	Interleukin-2 Production by Polyfunctional HIV-1–Specific CD8 T Cells Is Associated With Enhanced Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 132-140.	0.9	40
53	Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial. PLoS ONE, 2011, 6, e24517.	1.1	39
54	An Endoplasmic Reticulum Retrieval Signal Partitions Human Foamy Virus Maturation to Intracytoplasmic Membranes. Journal of Virology, 1999, 73, 7210-7217.	1.5	35

#	Article	IF	CITATIONS
55	The HIV-1 Antisense Protein (ASP) induces CD8 T cell responses during chronic infection. Retrovirology, 2015, 12, 15.	0.9	34
56	Cross-Reactive CD8+ T Cell Epitopes Identified in US Adolescent Minorities. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 426-438.	0.9	33
57	Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents. Aids, 2007, 21, 2387-2397.	1.0	32
58	HIV-1–Specific CD8 T Cells Exhibit Limited Cross-Reactivity during Acute Infection. Journal of Immunology, 2016, 196, 3276-3286.	0.4	31
59	Duration of post-COVID-19 symptoms are associated with sustained SARS-CoV-2 specific immune responses. JCI Insight, 2021, 6, .	2.3	31
60	Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV-1 disease progression. Journal of Experimental Medicine, 2016, 213, 2049-2063.	4.2	30
61	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. PLoS ONE, 2017, 12, e0179597.	1.1	29
62	KIR2DS4 Promotes HIV-1 Pathogenesis: New Evidence from Analyses of Immunogenetic Data and Natural Killer Cell Function. PLoS ONE, 2014, 9, e99353.	1.1	28
63	Normal T-cell activation in elite controllers with preserved CD4+ T-cell counts. Aids, 2015, 29, 2245-2254.	1.0	27
64	Menstrual Blood as a Potential Source of Endometrial Derived CD3+ T Cells. PLoS ONE, 2011, 6, e28894.	1.1	26
65	Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients. Aids, 2014, 28, 2627-2631.	1.0	26
66	Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. Cell Reports Medicine, 2021, 2, 100164.	3.3	26
67	Diminished CD103 (aEb7) Expression on Resident T cells from the Female Genital Tract of HIV-positive women. Pathogens and Immunity, 2016, 1, 371.	1.4	23
68	Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. Aids, 2008, 22, 957-962.	1.0	22
69	Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection. Journal of Virology, 2015, 89, 6656-6672.	1.5	22
70	Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals. Vaccine, 2020, 38, 1778-1786.	1.7	22
71	Characterization of the R572T Point Mutant of a Putative Cleavage Site in Human Foamy Virus Env. Journal of Virology, 2000, 74, 2949-2954.	1.5	20
72	Functionally Competent Antigenâ€Specific CD127hiMemory CD8+T Cells Are Preserved Only in HIVâ€Infected Individuals Receiving Early Treatment. Journal of Infectious Diseases, 2007, 195, 108-117.	1.9	20

#	Article	IF	CITATIONS
73	HLA Class-II Associated HIV Polymorphisms Predict Escape from CD4+ T Cell Responses. PLoS Pathogens, 2015, 11, e1005111.	2.1	20
74	Dysregulation of Systemic and Mucosal Humoral Responses to Microbial and Food Antigens as a Factor Contributing to Microbial Translocation and Chronic Inflammation in HIV-1 Infection. PLoS Pathogens, 2017, 13, e1006087.	2.1	19
75	Analysis of West African Hunters for Foamy Virus Infections. AIDS Research and Human Retroviruses, 1996, 12, 1725-1730.	0.5	18
76	Host Factor Transcriptional Regulation Contributes to Preferential Expression of HIV Type 1 in IL-4–Producing CD4 T Cells. Journal of Immunology, 2012, 189, 2746-2757.	0.4	18
77	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. Science Translational Medicine, 2019, 11, .	5.8	18
78	Reply to Jakovac and to Rocha et al.: Can vitamin D prevent or manage COVID-19 illness?. American Journal of Physiology - Endocrinology and Metabolism, 2020, 319, E455-E457.	1.8	18
79	Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. Journal of AIDS & Clinical Research, 2015, 06, .	0.5	17
80	CD8 T cells targeting adapted epitopes in chronic HIV infection promote dendritic cell maturation and CD4 T cell trans-infection. PLoS Pathogens, 2019, 15, e1007970.	2.1	14
81	Understanding the CD8 T-cell response in natural HIV control. F1000Research, 2018, 7, 985.	0.8	14
82	CD151 Expression Is Associated with a Hyperproliferative T Cell Phenotype. Journal of Immunology, 2017, 199, 3336-3347.	0.4	12
83	Better Viral Control despite Higher CD4 ⁺ T Cell Activation during Acute HIV-1 Infection in Zambian Women Is Linked to the Sex Hormone Estradiol. Journal of Virology, 2020, 94, .	1.5	12
84	HLA-E–restricted HIV-1–specific CD8+ T cell responses in natural infection. Journal of Clinical Investigation, 2021, 131, .	3.9	12
85	Characterization of Type-I IFN subtype autoantibodies and activity in SLE serum and urine. Lupus, 2020, 29, 1095-1105.	0.8	11
86	Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants. Vaccine Journal, 2014, 21, 1589-1599.	3.2	10
87	Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 1-8.	0.9	10
88	Progressive lentivirus infection induces natural killer cell receptor-expressing B cells in the gastrointestinal tract. Aids, 2018, 32, 1571-1578.	1.0	10
89	HLA-I Associated Adaptation Dampens CD8 T-Cell Responses in HIV Ad5-Vectored Vaccine Recipients. Journal of Infectious Diseases, 2019, 220, 1620-1628.	1.9	10
90	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. Scientific Reports, 2020, 10, 13031.	1.6	10

#	Article	IF	CITATIONS
91	Immune Activation Is Associated with CD8 T Cell Interleukin-21 Production in HIV-1-Infected Individuals. Journal of Virology, 2014, 88, 10259-10263.	1.5	9
92	Use of Dried Blood Spots to Elucidate Full-Length Transmitted/Founder HIV-1 Genomes. Pathogens and Immunity, 2016, 1, 129.	1.4	9
93	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. Npj Vaccines, 2021, 6, 56.	2.9	7
94	Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine. Journal of Infectious Diseases, 2022, 226, 979-982.	1.9	7
95	Cross-Reactive CD8 T-Cell Responses Elicited by Adenovirus Type 5-Based HIV-1 Vaccines Contributed to Early Viral Evolution in Vaccine Recipients Who Became Infected. Journal of Virology, 2020, 94, .	1.5	6
96	Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies. Protein Engineering, Design and Selection, 2022, 35, .	1.0	6
97	Human Immunodeficiency Virus Vaccines. Infectious Disease Clinics of North America, 2014, 28, 615-631.	1.9	5
98	Characterization of T-Cell Responses to Cryptic Epitopes in Recipients of a Noncodon-Optimized HIV-1 Vaccine. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 142-150.	0.9	4
99	Mechanistic inferences from clinical reports of SARS-CoV-2. Infectious Diseases, 2020, 52, 527-537.	1.4	4
100	Elevated HIV Infection of CD4 T Cells in MRKAd5 Vaccine Recipients Due to CD8 T Cells Targeting Adapted Epitopes. Journal of Virology, 2021, 95, e0016021.	1.5	4
101	CD4 + T cells from HIV-1 patients with impaired Th1 effector responses to Mycobacterium tuberculosis exhibit diminished histone and nucleoprotein signatures. Clinical Immunology, 2017, 181, 16-23.	1.4	3
102	Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection. Journal of Virology, 2018, 92, .	1.5	3
103	Cross-Reactivity to Mutated Viral Immune Targets Can Influence CD8+ T Cell Functionality: An Alternative Viral Adaptation Strategy. Frontiers in Immunology, 2021, 12, 746986.	2.2	3
104	Safety and immunogenicity of monovalent H7N9 influenza vaccine with ASO3 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial. Vaccine, 2022, 40, 3253-3262.	1.7	3
105	Dynamics and Correlates of CD8 T-Cell Counts in Africans with Primary Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2016, 90, 10423-10430.	1.5	2
106	Short Communication: Apoptotic Membrane Microparticles Quantified by Fluorescent Bead-Based Assay Are Elevated in HIV and SIV Infections. AIDS Research and Human Retroviruses, 2018, 34, 446-448.	0.5	1
107	Immunogenetic factors in early immune control of human immunodeficiency virus type 1 (HIV-1) infection: Evaluation of HLA class I amino acid variants in two African populations. Human Immunology, 2018, 79, 166-171.	1.2	1
108	AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. Vaccine, 2021, 39, 4641-4650.	1.7	1

#	Article	IF	CITATIONS
109	Human Immunodeficiency Viruses Types 1 and 2. , 2014, , 1001-1062.		0